Predictive Value of Tumor Regression Grading on the Prognosis of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.
Ruchen Wu, Shuying Lin, Junze Chen, Gang Wang, Lulu Han
{"title":"Predictive Value of Tumor Regression Grading on the Prognosis of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.","authors":"Ruchen Wu, Shuying Lin, Junze Chen, Gang Wang, Lulu Han","doi":"10.14309/ctg.0000000000000860","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tumor regression grade (TRG) following neoadjuvant chemotherapy is recognized as a significant and favorable prognostic indicator in various cancer types. However, this relationship remains less defined and has not been systematically investigated in local advanced gastric cancer (LAGC). To address this gap, we conducted a meta-analysis aimed at assessing the prognostic influence of tumor regression after preoperative therapy on disease-free survival (DFS) and overall survival (OS) among patients with LAGC.</p><p><strong>Methods: </strong>A systematic search was conducted across the following databases: PubMed, Web of Science, Embase, Cochrane, WF, CNKI, SinoMed, and VIP. The primary outcomes included DFS and OS, estimated using hazard ratios (HR) and corresponding 95% confidence intervals (95% CI). Subsequently, either the fixed-effects model or the random-effects model was employed to compute HR and 95% CI based on the results of heterogeneity analysis.</p><p><strong>Results: </strong>A total of 11 studies, comprising 2,733 patients, were included in the final analysis. The results indicated that a lower TRG was associated with prolonged DFS (HR = 0.53, 95% CI: 0.32-0.88) and prolonged OS (HR = 0.59, 95% CI: 0.39-0.87) in patients with LAGC who received neoadjuvant chemotherapy. Sensitivity analysis demonstrated that no single study significantly influenced the results for both DFS and OS. Publication bias was identified in the meta-analysis for OS, whereas no publication bias was detected in the meta-analysis for DFS.</p><p><strong>Conclusion: </strong>A lower TRG score is associated with improved DFS and OS in patients with LAGC receiving neoadjuvant chemotherapy.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000860","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Tumor regression grade (TRG) following neoadjuvant chemotherapy is recognized as a significant and favorable prognostic indicator in various cancer types. However, this relationship remains less defined and has not been systematically investigated in local advanced gastric cancer (LAGC). To address this gap, we conducted a meta-analysis aimed at assessing the prognostic influence of tumor regression after preoperative therapy on disease-free survival (DFS) and overall survival (OS) among patients with LAGC.
Methods: A systematic search was conducted across the following databases: PubMed, Web of Science, Embase, Cochrane, WF, CNKI, SinoMed, and VIP. The primary outcomes included DFS and OS, estimated using hazard ratios (HR) and corresponding 95% confidence intervals (95% CI). Subsequently, either the fixed-effects model or the random-effects model was employed to compute HR and 95% CI based on the results of heterogeneity analysis.
Results: A total of 11 studies, comprising 2,733 patients, were included in the final analysis. The results indicated that a lower TRG was associated with prolonged DFS (HR = 0.53, 95% CI: 0.32-0.88) and prolonged OS (HR = 0.59, 95% CI: 0.39-0.87) in patients with LAGC who received neoadjuvant chemotherapy. Sensitivity analysis demonstrated that no single study significantly influenced the results for both DFS and OS. Publication bias was identified in the meta-analysis for OS, whereas no publication bias was detected in the meta-analysis for DFS.
Conclusion: A lower TRG score is associated with improved DFS and OS in patients with LAGC receiving neoadjuvant chemotherapy.
期刊介绍：
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
